Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
humans (8) 8
male (8) 8
female (7) 7
middle aged (7) 7
aged (5) 5
cancer (5) 5
lung cancer (5) 5
survival (5) 5
adult (4) 4
care and treatment (4) 4
chemotherapy (4) 4
lung cancer, non-small cell (4) 4
medicine, general & internal (4) 4
metastasis (4) 4
oncology (4) 4
aged, 80 and over (3) 3
analysis (3) 3
hematology, oncology and palliative medicine (3) 3
lung neoplasms - drug therapy (3) 3
motivation (3) 3
mutation (3) 3
toxicity (3) 3
abridged index medicus (2) 2
bevacizumab (2) 2
brain neoplasms - secondary (2) 2
cancer therapies (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
cell survival (2) 2
cisplatin (2) 2
clinical trials (2) 2
college teachers (2) 2
crizotinib (2) 2
epidermal growth factor receptors (2) 2
gefitinib (2) 2
gene (2) 2
interactive systems (2) 2
internal medicine (2) 2
kinases (2) 2
lung neoplasms - genetics (2) 2
lung neoplasms - pathology (2) 2
magnetic resonance imaging (2) 2
medical colleges (2) 2
metastases (2) 2
oncology, experimental (2) 2
patients (2) 2
pharmaceuticals (2) 2
platinum (2) 2
product development (2) 2
prognosis (2) 2
recruitment (2) 2
research (2) 2
respiratory agents (2) 2
risk (2) 2
risk factors (2) 2
treatment outcome (2) 2
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - metabolism (1) 1
adenocarcinoma - pathology (1) 1
adenocarcinoma - radiotherapy (1) 1
adenocarcinoma - secondary (1) 1
advanced nsclc (1) 1
af-001jp (1) 1
anaplastic lymphoma (1) 1
anaplastic lymphoma kinase (1) 1
angina (1) 1
angina, stable - epidemiology (1) 1
anorexia (1) 1
anti-infective agents - administration & dosage (1) 1
anti-infective agents - adverse effects (1) 1
anti-inflammatory agents, non-steroidal - administration & dosage (1) 1
antibiotic prophylaxis - methods (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
apoptosis (1) 1
articles (1) 1
asymptomatic brain metastases (1) 1
audio frequencies (1) 1
bayesian analysis (1) 1
bevacizumab - therapeutic use (1) 1
biomarkers - metabolism (1) 1
bleomycin hamster model (1) 1
brain - diagnostic imaging (1) 1
brain - pathology (1) 1
brain - surgery (1) 1
brain metastasis (1) 1
brain neoplasms - diagnostic imaging (1) 1
brain neoplasms - pathology (1) 1
brain neoplasms - prevention & control (1) 1
brain neoplasms - radiotherapy (1) 1
brain research (1) 1
c-met (1) 1
cancer patients (1) 1
carbazoles - pharmacokinetics (1) 1
carbazoles - therapeutic use (1) 1
carbon monoxide - metabolism (1) 1
carboplatin (1) 1
carcinoma, large cell - drug therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
by Hida, Toyoaki, MD and Nokihara, Hiroshi, MD and Kondo, Masashi, MD and Kim, Young Hak, MD and Azuma, Koichi, MD and Seto, Takashi, MD and Takiguchi, Yuichi, Prof and Nishio, Makoto, MD and Yoshioka, Hiroshige, MD and Imamura, Fumio, MD and Hotta, Katsuyuki, Prof and Watanabe, Satoshi, MD and Goto, Koichi, MD and Satouchi, Miyako, MD and Kozuki, Toshiyuki, MD and Shukuya, Takehito, MD and Nakagawa, Kazuhiko, Prof and Mitsudomi, Tetsuya, Prof and Yamamoto, Nobuyuki, Prof and Asakawa, Takashi, PhD and Asabe, Ryoichi, MS and Tanaka, Tomohiro, MS and Tamura, Tomohide, Dr
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
by Mitsudomi, Tetsuya, Dr and Morita, Satoshi, Prof and Yatabe, Yasushi, MD and Negoro, Shunichi, MD and Okamoto, Isamu, MD and Tsurutani, Junji, MD and Seto, Takashi, MD and Satouchi, Miyako, MD and Tada, Hirohito, MD and Hirashima, Tomonori, MD and Asami, Kazuhiro, MD and Katakami, Nobuyuki, MD and Takada, Minoru, Prof and Yoshioka, Hiroshige, MD and Shibata, Kazuhiko, MD and Kudoh, Shinzoh, MD and Shimizu, Eiji, Prof and Saito, Hiroshi, MD and Toyooka, Shinichi, MD and Nakagawa, Kazuhiko, Prof and Fukuoka, Masahiro, Prof and W Japan Oncology Grp and West Japan Oncology Group
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 121 - 128
Summary Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor ( EGFR ) gene respond well to the... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | MULTICENTER | GENE | EFFICACY | ONCOLOGY | CLINICAL-TRIALS | EGFR MUTATIONS | II TRIAL | JAPANESE PATIENTS | CHEMOTHERAPY | PREVIOUSLY TREATED PATIENTS | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Taxoids - administration & dosage | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Tyrosine | Medical colleges | Care and treatment | Molecular genetics | Clinical trials | Respiratory agents | Lung cancer, Non-small cell | Chemotherapy | Cancer patients | Epidermal growth factor | Product development | Gefitinib | Cancer | Index Medicus | Liver diseases | Epidermal growth factor receptors | Exons | Toxicity | Hypersensitivity | Lung cancer | Diarrhea | Fatigue | Gene deletion | Survival | Cisplatin | Recruitment | Hospitals | Point mutation | Myelosuppression | Pharmaceuticals | Thyroid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
by Seto, Takashi, MD and Kiura, Katsuyuki, Prof and Nishio, Makoto, MD and Nakagawa, Kazuhiko, Prof and Maemondo, Makoto, MD and Inoue, Akira, MD and Hida, Toyoaki, MD and Yamamoto, Nobuyuki, MD and Yoshioka, Hiroshige, MD and Harada, Masao, MD and Ohe, Yuichiro, MD and Nogami, Naoyuki, MD and Takeuchi, Kengo, MD and Shimada, Tadashi, MS and Tanaka, Tomohiro, MS and Tamura, Tomohide, Dr
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
by Takahashi, Toshiaki, MD and Yamanaka, Takeharu, Prof and Seto, Takashi, MD and Harada, Hideyuki, MD and Nokihara, Hiroshi, MD and Saka, Hideo, MD and Nishio, Makoto, MD and Kaneda, Hiroyasu, MD and Takayama, Koichi, MD and Ishimoto, Osamu, MD and Takeda, Koji, MD and Yoshioka, Hiroshige, MD and Tachihara, Motoko, MD and Sakai, Hiroshi, MD and Goto, Koichi, MD and Yamamoto, Nobuyuki, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Summary Background Results from a previous phase 3 study suggested that prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases... 
Hematology, Oncology and Palliative Medicine | DIAGNOSIS | METAANALYSIS | THERAPY | COMPLETE REMISSION | CISPLATIN | ONCOLOGY | RISK | ASYMPTOMATIC BRAIN METASTASES | Lung Neoplasms - drug therapy | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - secondary | Early Termination of Clinical Trials | Brain Neoplasms - secondary | Aged, 80 and over | Medical Futility | Adult | Female | Survival Rate | Cranial Irradiation - adverse effects | Brain Neoplasms - prevention & control | Small Cell Lung Carcinoma - prevention & control | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Small Cell Lung Carcinoma - diagnostic imaging | Watchful Waiting | Aged | Platinum Compounds - administration & dosage | Care and treatment | Chemotherapy | Lung cancer | Oncology, Experimental | Radiation | Clinical trials | Metastasis | Research | College teachers | Radiotherapy | Cancer | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Reenlargement of radiation necrosis after stereotactic radiotherapy for brain metastasis from lung cancer during bevacizumab treatment
by Furuuchi, Koji, MD and Nishiyama, Akihiro, MD and Yoshioka, Hiroshige, MD, PhD and Yokoyama, Toshihide, MD and Ishida, Tadashi, MD, PhD
Respiratory Investigation, ISSN 2212-5345, 2016, Volume 55, Issue 2, pp. 184 - 187
Abstract We describe a 55-year-old man who received stereotactic radiotherapy (SRT) for the treatment of brain metastasis from lung adenocarcinoma. Fourteen... 
Internal Medicine | Pulmonary/Respiratory | Lung cancer | Brain metastasis | Stereotactic radiotherapy | Radiation necrosis | Bevacizumab | Necrosis - drug therapy | Brain - diagnostic imaging | Adenocarcinoma - pathology | Bevacizumab - therapeutic use | Humans | Middle Aged | Brain Neoplasms - pathology | Lung Neoplasms - pathology | Male | Necrosis - surgery | Radiosurgery - adverse effects | Adenocarcinoma - secondary | Necrosis - diagnostic imaging | Magnetic Resonance Imaging | Brain Neoplasms - secondary | Necrosis - etiology | Brain - pathology | Brain - surgery | Brain Neoplasms - radiotherapy | Adenocarcinoma - radiotherapy | Usage | Analysis | Radiosurgery | Metastasis | Drug therapy | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a... 
MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | BEVACIZUMAB | CRIZOTINIB | NIVOLUMAB | PACLITAXEL | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Slopes | Lung cancer | Oncology | Kinases | Cancer therapies | Metastases | Pembrolizumab | Randomization | Motivation | Platinum | Risk assessment | Population | Translocation | Cell survival | Life expectancy | Epidermal growth factor receptors | Hyperthyroidism | Histology | Hypothyroidism | Survival | Patients | Medical centres | Life span | Interactive systems | PD-L1 protein | Men | Ligands | Mutation | Tumors | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The number of microvascular complications is associated with an increased risk for severity of periodontitis in type 2 diabetes patients: Results of a multicenter hospital‐based cross‐sectional study
by Nitta, Hiroshi and Katagiri, Sayaka and Nagasawa, Toshiyuki and Izumi, Yuichi and Ishikawa, Isao and Izumiyama, Hajime and Uchimura, Isao and Kanazawa, Masao and Chiba, Hiroshige and Matsuo, Akira and Utsunomiya, Kazunori and Tanabe, Haruyasu and Takei, Izumi and Asanami, Soichiro and Kajio, Hiroshi and Ono, Toaki and Hayashi, Yoichi and Ueki, Kiichi and Tsuji, Masatomi and Kurachi, Yoichi and Yamanouchi, Toshikazu and Ichinokawa, Yoshimi and Inokuchi, Toshiki and Fukui, Akiko and Miyazaki, Shigeru and Miyauchi, Takashi and Kawahara, Reiko and Ogiuchi, Hideki and Yoshioka, Narihito and Negishi, Jun and Mori, Masatomo and Mogi, Kenji and Saito, Yasushi and Tanzawa, Hideki and Nishikawa, Tetsuo and Takada, Norihiko and Nanjo, Kishio and Morita, Nobuo and Nakamura, Naoto and Kanamura, Narisato and Makino, Hirofumi and Nishimura, Fusanori and Kobayashi, Kunihisa and Higuchi, Yoshinori and Sakata, Toshiie and Yanagisawa, Shigetaka and Tei, Chuwa and Ando, Yuichi and Hanada, Nobuhiro and Inoue, Shuji
Journal of Diabetes Investigation, ISSN 2040-1116, 09/2017, Volume 8, Issue 5, pp. 677 - 686
We explored the relationship between microvascular complications and periodontitis, and glycemic control status and periodontitis in type 2 diabetic patients... 
Type 2 diabetes | Microangiopathy | Periodontitis | GINGIVA | GLYCEMIC CONTROL | DISEASE | ENDOCRINOLOGY & METABOLISM | RETINOPATHY | MELLITUS | HEALTH | Severity of Illness Index | Microvessels - physiopathology | Cross-Sectional Studies | Humans | Middle Aged | Risk Factors | Male | Diabetes Mellitus, Type 2 - epidemiology | Aged, 80 and over | Adult | Female | Aged | Periodontitis - complications | Periodontitis - epidemiology | Diabetes Mellitus, Type 2 - complications | Glycosylated hemoglobin | Risk factors | Confidence intervals | Diabetes mellitus | Teeth | Hemoglobin | Microvasculature | Glucose | Diabetes | Geriatrics | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Identifying the Cause of the "Saturation Gap": Two Cases of Dapsone-induced Methemoglobinemia
by Furuta, Kenjiro and Ikeo, Satoshi and Takaiwa, Takuya and Ikeda, Satoshi and Nishiyama, Akihiro and Yokoyama, Toshihide and Ito, Akihiro and Tokioka, Fumiaki and Tanaka, Maki and Yoshioka, Hiroshige and Tachibana, Hiromasa and Arita, Machiko and Hashimoto, Toru and Ishida, Tadashi
Internal Medicine, ISSN 0918-2918, 2015, Volume 54, Issue 13, pp. 1639 - 1641
Diaphenylsulfone (DDS: Dapsone) is used for Pneumocystis pneumonia (PCP) prophylaxis, and methemoglobinemia has rarely been reported as a side effect of DDS.... 
dapsone | saturation gap | diaphenylsulfone | methemoglobinemia | PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PNEUMOCYSTIS-CARINII-PNEUMONIA | INFECTED PATIENTS | Dapsone - adverse effects | Anti-Infective Agents - adverse effects | Cryptogenic Organizing Pneumonia - drug therapy | Humans | Antibiotic Prophylaxis - methods | Pneumonia, Pneumocystis - prevention & control | Male | Treatment Outcome | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Anti-Infective Agents - administration & dosage | Methemoglobinemia - drug therapy | Dapsone - administration & dosage | Aged, 80 and over | Female | Methemoglobinemia - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis
by Konishi, Satoshi and Arita, Machiko and Ito, Isao and Tachibana, Hiromasa and Takaiwa, Takuya and Fukuda, Yasushi and Watanabe, Naoki and Tsubouchi, Kazuya and Masuda, Gen and Tanaka, Maki and Kourogi, Youhei and Kunimasa, Kei and Nishiyama, Akihiro and Iwasaku, Masahiro and Ito, Akihiro and Tokioka, Fumiaki and Yoshioka, Hiroshige and Hashimoto, Toru and Ishida, Tadashi
Internal Medicine, ISSN 0918-2918, 2015, Volume 54, Issue 22, pp. 2835 - 2841
Objective The goals of this study were to assess the efficacy and tolerability of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) and to... 
idiopathic pulmonary fibrosis | composite physiologic index | interstitial lung disease | pirfenidone | emphysema | SURVIVAL | TRIAL | LUNG FIBROSIS | MEDICINE, GENERAL & INTERNAL | PHASE | BLEOMYCIN HAMSTER MODEL | LEVEL | Biomarkers - metabolism | Predictive Value of Tests | Humans | Middle Aged | Male | Treatment Outcome | Lung - physiopathology | Carbon Monoxide - metabolism | Disease Progression | Dose-Response Relationship, Drug | Vital Capacity - drug effects | Pyridones - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Adult | Female | Idiopathic Pulmonary Fibrosis - physiopathology | Retrospective Studies | Idiopathic Pulmonary Fibrosis - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
by Eisen, Alon and Bhatt, Deepak L and Steg, P. Gabriel and Eagle, Kim A and Goto, Shinya and Guo, Jianping and Smith, Sidney C and Ohman, E. Magnus and Scirica, Benjamin M and REACH Registry Investigators and the REACH Registry Investigators
Journal of the American Heart Association, ISSN 2047-9980, 10/2016, Volume 5, Issue 10, p. n/a
Background The extent to which angina is associated with future cardiovascular events in patients with coronary artery disease has long been debated. Methods... 
cardiovascular events | coronary artery disease | angina | Cardiovascular events | Coronary artery disease | Angina | CARDIAC & CARDIOVASCULAR SYSTEMS | OUTPATIENTS | MYOCARDIAL-ISCHEMIA | RISK | SYMPTOMS | RATES | HEART-DISEASE | SOUL | PECTORIS | CLARIFY REGISTRY | CLINICAL-OUTCOMES | United States - epidemiology | Myocardial Infarction - epidemiology | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Hospitalization - statistics & numerical data | Male | Case-Control Studies | Myocardial Revascularization - utilization | Angina, Stable - epidemiology | Cardiovascular Diseases - mortality | Female | Registries | Stroke - epidemiology | Aged | Coronary Artery Disease - epidemiology | Odds Ratio | Heart Failure - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.